Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410188 · ClinicalTrials.gov registry record · Phase 1
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT01410188 is a Phase 1 study that has completed, run by Kubota Vision. The registered enrollment target is 160 participants.
The verdict
NCT01410188, a Phase 1 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Placebo
- DRUG Latanoprost
- DRUG OPA-6566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410188
The ClinicalTrials.gov registry entry for NCT01410188 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01410188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410188 about?
NCT01410188 is a clinical study titled "Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension". This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01410188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2011-09. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01410188?
The interventions under investigation include: Placebo (DRUG), Latanoprost (DRUG), OPA-6566 (DRUG).
Who is sponsoring clinical trial NCT01410188?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.